Patents by Inventor Zoya Alteber

Zoya Alteber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PVRL2 AND/OR PVRIG AS BIOMARKERS FOR TREATMENT
    Publication number: 20240103010
    Abstract: The present invention provides biomarkers for use in determining populations for treatment with anti-PVRIG antibodies and such biomarkers include, for example PVRIG and/or PVRL2 expression.
    Type: Application
    Filed: March 17, 2023
    Publication date: March 28, 2024
    Inventors: Roy Z. Granit, Gad S. Cojocaru, Eran Ophir, Amit Novik, Niv Sabath, Zoya Alteber
  • ANTI-PVRIG ANTIBODIES FORMULATIONS AND USES THEREOF
    Publication number: 20240082397
    Abstract: The present invention is directed to anti-PVRIG antibodies and stable liquid pharmaceutical formulations thereof. The present invention is directed to monotherapy and combination treatments with anti-PVRIG antibodies and anti-PD-1 antibodies, in particular nivolumab, using stable liquid pharmaceutical formulations thereof.
    Type: Application
    Filed: January 28, 2022
    Publication date: March 14, 2024
    Inventors: Mark WHITE, Inbal BARBIRO, Ilan VAKNIN, Assaf WOOL, Zurit LEVINE, Henry Adeboye ADEWOYE, MD, Michael BUCKLEY, Jun LU, John HUNTER, Anat COHEN-DAYAG, Gad S. COJOCARU, Eran OPHIR, Zoya ALTEBER
  • COMBINATION THERAPY WITH ANTI-PVRIG ANTIBODIES FORMULATIONS AND ANTI-PD-1 ANTIBODIES
    Publication number: 20240076373
    Abstract: The present invention is directed to anti-PVRIG antibodies and stable liquid pharmaceutical formulations thereof. The present invention is directed to monotherapy and combination treatments with anti-PVRIG antibodies and anti-PD-1 antibodies, in particular nivolumab, using stable liquid pharmaceutical formulations thereof. The present invention also provides biomarkers for use in determining populations for treatment with anti-PVRIG antibodies and such biomarkers include, for example PVRIG and/or PVRL2 expression.
    Type: Application
    Filed: January 28, 2022
    Publication date: March 7, 2024
    Inventors: Inbal BARBIRO, Ilan VAKNIN, Assaf WOOL, Zurit LEVINE, Paul A. BASCIANO, Brian D. LAMON, Henry Adeboye ADEWOYE, John HUNTER, Anat COHEN-DAYAG, Gad S. COJOCARU, Eran OPHIR, Zoya ALTEBER
  • PVRL2 AND/OR PVRIG AS BIOMARKERS FOR TREATMENT
    Publication number: 20230400467
    Abstract: The present invention provides biomarkers for use in determining populations for treatment with anti-PVRIG antibodies and such biomarkers include, for example PVRIG and/or PVRL2 expression.
    Type: Application
    Filed: October 26, 2021
    Publication date: December 14, 2023
    Inventors: Gad S. COJOCARU, Tal Fridman KFIR, Emmanuel WEYL, Amit NOVIK, Yossef KLIGER, Niv SABATH, Eran OPHIR, Zoya ALTEBER, Masha FRENKEL
  • TRIPLE COMBINATION ANTIBODY THERAPIES
    Publication number: 20230070685
    Abstract: The present invention is directed to triple combination therapies with anti-TIGIT antibodies, anti-PVRIG antibodies, and checkpoint inhibitors, including anti-PD-1 or anti-PD-L1 antibodies.
    Type: Application
    Filed: December 7, 2021
    Publication date: March 9, 2023
    Inventors: Spencer Liang, Ling Leung, Sarah Whelan, Maya Kotturi, Eran Ophir, Arthur Machlenkin, Zoya Alteber, Meir Azulay, Sandeep Kumar, Radhika Desai, Christopher Chan, Kathryn Logronio
  • Triple combination antibody therapies
    Patent number: 11225523
    Abstract: The present invention is directed to triple combination therapies with anti-TIGIT antibodies, anti-PVRIG antibodies, and checkpoint inhibitors, including anti-PD-1 or anti-PD-L1 antibodies.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: January 18, 2022
    Assignee: Compugen Ltd.
    Inventors: Spencer Liang, Ling Leung, Sarah Whelan, Maya Kotturi, Eran Ophir, Arthur Machlenkin, Zoya Alteber, Meir Azulay, Sandeep Kumar, Radhika Desai, Christopher Chan, Kathryn Logronio
  • TRIPLE COMBINATION ANTIBODY THERAPIES
    Publication number: 20190010246
    Abstract: The present invention is directed to triple combination therapies with anti-TIGIT antibodies, anti-PVRIG antibodies, and checkpoint inhibitors, including anti-PD-1 or anti-PD-L1 antibodies.
    Type: Application
    Filed: June 1, 2018
    Publication date: January 10, 2019
    Inventors: Spencer Liang, Ling Leung, Sarah Whelan, Maya Kotturi, Eran Ophir, Arthur Machlenkin, Zoya Alteber, Meir Azulay, Sandeep Kumar, Radhika Desai, Christopher Chan, Kathryn Logronio